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plex and not yet fully understood, but the disease is now
recognized as being associated with ocular surface inﬂam-
mation. The latest advances in the understanding of the
pathophysiology of DED have directed the focus of recent
drug development to target the inﬂammatory pathways
involved in the disease. Liﬁtegrast is a novel small molecule
integrin antagonist that inhibits T cell-mediated inﬂamma-
tion by blocking the binding of two important cell surface
proteins (lymphocyte function-associated antigen 1 and
intercellular adhesion molecule 1), thus lessening overall
inﬂammatory responses. This review highlights the role of
T cells and integrins in the inﬂammatory process involved in
the pathophysiology of DED and outlines the scientiﬁc
rationale for the role of liﬁtegrast. In addition, the preclinical
development, pharmacological properties, clinical efﬁcacy,
and safety of liﬁtegrast are described.Accepted for publication January 2016.
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integrin antagonist, LFA-1, liﬁtegrastI. INTRODUCTIOND ry eye disease (DED; also referred to as keratocon-junctivitis sicca or dry eye syndrome) is a multifac-torial disorder, characterized by either decreased
tear production or increased tear ﬁlm evaporation,1 which
affects both the ocular surface and the lacrimal gland.
Although its pathogenesis is not yet fully elucidated, DED
is now recognized as a disease associated with ocular surface
inﬂammation.1 Indeed, the inﬁltration of T cells in the
lacrimal functional unit, including the conjunctiva and
lacrimal glands, is known to result in chronic inﬂammation.
The role of T cells is pivotal in the development of cell-
mediated immune responses. More speciﬁcally, CD4
positive (D) T helper (TH) 1 and TH17 T cells have been
identiﬁed as mediators of ocular surface inﬂammation in
DED.2 Recruitment and activation of these T cells at the
ocular surface lead to the release of effector cytokines and
contribute to the ocular tissue damage seen in patients
with DED. In fact, proinﬂammatory cytokines have been
detected in the tear ﬁlm of patients with DED.3,4 Therefore,
it is hoped that therapies targeting T cells will provide a
more efﬁcient means to treat DED.
Currently available treatments include immunomodula-
tors and immunosuppressive agents (e.g., ophthalmic cyclo-
sporine [Restasis]5 and ophthalmic corticosteroids).1
Ophthalmic cyclosporine is presently the only approved pre-
scription therapy for use in patients with DED in the United
States and Canada. Despite the progress made in recent
years in the understanding of the pathophysiology of
DED, there is at present no single on- or off-label medica-
tion that displays all the following characteristics and bene-
ﬁts of an ideal DED agent: 1) exhibits good tolerability and
long-term safety, 2) has a rapid onset of action, 3) targets
key steps of the inﬂammation cycle, and, most importantly,
4) treats both signs and symptoms of DED. Thus, there is an
unmet need for new and effective DED therapies, and the
recent focus of drug development has been to ﬁnd novel
compounds targeting inﬂammation.. 14 NO. 2 / www.theocularsurface.com 207
OUTLINE
I. Introduction
II. Role of T Cells, Integrins, and Adhesion Ligands in the
Inﬂammatory Process and Dry Eye Disease
A. Immunology of DED
B. Integrin Signaling in the Immunoinﬂammatory
Pathway
III. Development of Liﬁtegrast, an Integrin Antagonist, as
a Treatment for Dry Eye Disease
A. Discovery and Development of Liﬁtegrast
B. Mechanism of Action of Liﬁtegrast at the Molecular
and Cellular Levels
C. Liﬁtegrast: An Ophthalmic Agent for Treatment of
Dry Eye Disease
IV. Conclusion
Abbreviations
D Positive
APC Antigen-presenting cell
CYP450 Cytochrome P450
DED Dry eye disease
IC50 Half maximal inhibitory concentration
ICAM-1 Intercellular adhesion molecule 1
ICSS Inferior corneal staining score
IFN Interferon
IL-1 Interleukin 1
IS Immunological synapse
LFA-1 Lymphocyte function-associated antigen 1
MMP Matrix metalloproteinase
PK Pharmacokinetic
SD Standard deviation
TH T helper cell
TNF Tumor necrosis factor
Treg Regulatory T cell
LIFITEGRAST FOR TREATMENT OF DRY EYE / Perez, et alLiﬁtegrast is a novel small molecule integrin antagonist
that inhibits a speciﬁc T cell-mediated inﬂammatory pathway
involved in the pathogenesis of DED. Based on the current
understanding of its mechanism of action, liﬁtegrast blocks
the recruitment and activation of T cells to the ocular surface,
thus lessening overall inﬂammatory responses. If approved,
liﬁtegrast has the potential to be the ﬁrst treatment indicated
to treat both signs and symptoms of DED.
Herein, we review the role of T cells and integrins in the
inﬂammatory process involved in the pathophysiology of
DED and outline the scientiﬁc rationale for the role of liﬁte-
grast. In addition, the preclinical development, pharmaco-
logical properties, clinical efﬁcacy, and safety of liﬁtegrast
are described.II. ROLE OF T CELLS, INTEGRINS, AND ADHESION
LIGANDS IN THE INFLAMMATORY PROCESS AND DRY
EYE DISEASE
A. Immunology of DED
The pathology of DED is not yet fully understood, but
there is growing evidence that T cell-mediated inﬂammation
plays a central role in the disease.6,7 The role of T cells in DED
involves the following 6 steps: 1) uptake and processing of an-
tigens from the ocular tissue by antigen-presenting cells
(APC) on the ocular surface, 2) priming of T cells by APCs
in the lymphoid compartment, 3)migration of T cells through
the blood vessels, 4) recruitment of T cells to the conjunctival
stroma, 5) activation of T cells, and 6) retention of T cells into
inﬂamed tissues, as illustrated in Figure 1. Speciﬁcally, when
desiccating environmental stress is applied to the ocular sur-
face, it induces tear hyperosmolarity and the release of proin-
ﬂammatory cytokines (e.g., interleukin [IL]-1 and tumor
necrosis factor [TNF]-a) via activated kinases.8 This proin-
ﬂammatory milieu promotes the activation and maturation
of APCs. The migration of mature APCs to lymph nodes in
turn triggers the generation of autoreactive CD4þ T cells6
that journey to the ocular surface, where additional cytokines
are produced, thus causing further damage to the corneal
epithelium and conjunctival cells (Figure 1).208 THE OCULAR SURFACE / APRIL 2016, VUnderstanding the mechanisms involved in the onset
and progression of DED is key to the successful develop-
ment of effective therapeutic interventions. A number of
investigational studies and animal models of DED have
helped identify and quantify the T cell subtypes and bio-
markers (e.g., cytokines, chemokines, and ILs) of ocular
inﬂammation that are implicated in DED. CD4þ T cells,
which are found in ocular surface tissues of patients with
DED, are the primary inﬁltrating cells involved in
DED.2,9,10 CD4þ T cells can differentiate via divergent
pathways into 4 distinct subsets of T cells, namely TH1,
TH2, TH17, and regulatory T cells (Treg), depending on
which stimuli are driving the onset of inﬂammation.11
Recent human and experimental murine dry eye studies
showed that a TH1- and TH17-mediated immune response is
induced in the lymphoid compartment upon engagement
with mature APCs,4,9,12 as depicted in Figure 1. TH1 and
TH17 cells subsequently migrate to the ocular surface, where
they secrete additional markers of inﬂammation, in partic-
ular interferon (IFN)-g and IL-17, respectively.3,4 These cy-
tokines in turn promote the production and release of
various proinﬂammatory mediators (including cytokines,
chemokines, and matrix metalloproteinases [MMPs]) by
the conjunctival and corneal epithelium, thus creating a
self-perpetuating cycle of inﬂammation. Relative contribu-
tions of TH1 and TH17 cells to the pathogenesis of DED
are not fully understood, but evidence suggests that IFN-g
causes conjunctival goblet cell loss and apoptosis of the
ocular surface epithelium,3 while IL-17 stimulates the pro-
duction of MMPs that cause breakdown of the corneal
epithelial barrier.4 When damaged, the corneal epithelium
allows greater access of pathogens and inﬂammatory medi-
ators to the corneal epithelium and stroma (Figure 1),
events that may lead to decreased visual function for pa-
tients with DED.12OL. 14 NO. 2 / www.theocularsurface.com
Figure 1. The dry eye immunoinﬂammatory pathway. APC ¼ antigen-presenting cell; ICAM-1 ¼ intercellular adhesion molecule 1; IFN ¼ interferon;
IL ¼ interleukin; LFA-1 ¼ lymphocyte function-associated antigen 1; mAPC ¼ mature antigen-presenting cell; MMP ¼ matrix metalloproteinase; TH ¼ T
helper cell; TNF ¼ tumor necrosis factor; Treg ¼ regulatory T cell.
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LIFITEGRAST FOR TREATMENT OF DRY EYE / Perez, et alTaken together, these ﬁndings support the idea that
inhibiting T cell recruitment and activation by APCs during
the development of the inﬂammatory response in DED
should result in decreased levels of pathogenic mediators
and less inﬂammation on the ocular surface.
B. Integrin Signaling in the Immunoinﬂammatory
Pathway
Integrins are cell surface receptors involved in the inte-
gration between extracellular and intracellular signals in
many biological processes, including cytoskeletal organiza-
tion and cell adhesion, migration, proliferation, differentia-
tion, and survival.13 During an immune response,
integrins mediate 1) cell adhesion to the extracellular matrix,
and 2) cell-cell interactions (e.g., T cell activation), which are
central to the pathology of many inﬂammatory diseases,
including DED (Figure 1).
Naïve and memory T cells circulate freely in blood ves-
sels, monitoring for foreign antigens. Integrins are speciﬁc
heterodimeric receptors used by T cells to routinely migrate
in and out of lymph nodes when unchallenged, or into other
tissues following activation by an inﬂammatory signal.14 At
the beginning of an immune response, T cells need to be
able to access the site of inﬂammation by crossing the
vascular endothelium of blood vessels. This process is
enabled by a speciﬁc integrin expressed on T cells and
termed lymphocyte function-associated antigen 1 (LFA-1),
aLb2, or CD11a/CD18, through binding to its native ligand,
intercellular adhesion molecule 1 (ICAM-1). The expression
of LFA-1 is restricted to leukocytes, and LFA-1 is 1 of 12
integrins (out of the 24 known15) used by T cells to direct
their movement and function.14
ICAM-1, an adhesion protein expressed on a variety of
cells including APCs and endothelial cells, was ﬁrst proven
to be a ligand for LFA-1 in 1987 by Marlin and Springer.16
This discovery, together with additional studies, established
the understanding of the LFA-1/ICAM-1 pair as a key adhe-
sion pathway in T cell-mediated inﬂammation.17,18 Specif-
ically, the interaction of LFA-1 with ICAM-1 is important
not only for T cell adhesion to endothelial cells before trans-
endothelial migration to inﬂamed tissues, but also for T cell
interaction with APCs. At the site of inﬂammation, T cells
come into contact with APCs. Upon antigen presentation
and recognition, key receptors at the cell-cell interface reor-
ganize to enable the formation of an immunological synapse
(IS), which stabilizes once ICAM-1, expressed on APCs, is
bound to LFA-1.19,20 The mature IS in turn helps sustain
the otherwise transient interaction between the T cell and
the APC, which facilitates the propagation of downstream
proinﬂammatory factors, from the T cells themselves and
from other bystander cells (Figure 1). In the ocular surface,
T cells and corneal epithelial cells produce these signals (e.g.,
IFN-g, IL-17, TNF-a, IL-1) accordingly.
TNF-a and IL-1 are known to amplify the inﬂammatory
response by inducing the expression of ICAM-1 on epithe-
lial cells in patients with DED.21,22 LFA-1 also is upregulated
in the conjunctiva of patients with DED.23 The presence of210 THE OCULAR SURFACE / APRIL 2016, Vexcess ICAM-1 acts as an activating signal for patrolling
T cells in the conjunctival and corneal tissues. It drives the
recruitment of additional T cells to the ocular surface
through increased LFA-1 expression, thus contributing to
the perpetuation of inﬂammation. Based on the current un-
derstanding of DED, blocking the LFA-1/ICAM-1 interac-
tion could be a viable strategy for the prevention and
treatment of ocular surface inﬂammation.
Targeting integrin signaling has been shown to be a valid
drug discovery strategy and has allowed the development of
drugs with potent anti-inﬂammatory activities in various
autoimmune/inﬂammatory diseases.13 For example, efalizu-
mab (Raptiva),24 a recombinant humanized monoclonal
immunoglobulin G1 antibody against the a subunit of
LFA-1 (anti-CD11a), was one of the ﬁrst integrin antago-
nists to be marketed for the treatment of moderate to severe
psoriasis.15 It was designed to bind to LFA-1 and block its
function in T cell activation in lymph nodes, T cell adhesion
and extravasation to inﬂamed skin, and T cell reactivation in
the skin by APCs.25 Natalizumab (Tysabri)26 is another
approved drug (for the treatment of relapsing forms of mul-
tiple sclerosis) that targets an integrin pathway, speciﬁcally
the a4-integrin subunit.27 Targeting integrin signaling sys-
tematically can increase the risk of certain rare infections,
a side effect that would not be anticipated in a topical medi-
cation that reaches systemic circulation at extremely low
levels and then is rapidly excreted. Additionally, because liﬁ-
tegrast is a small molecule antagonist to a speciﬁc amino
acid sequence of ICAM-1 and not an antibody, it is expected
that associated side effects will be minimal.
Preclinical studies in various ocular diseases have shown
that inhibiting the interaction between integrins and their li-
gands, particularly LFA-1 and ICAM-1, holds promise as a
therapeutic approach. In a mouse model of induced allergic
conjunctivitis, it was established that the greatest inhibition
of cellular inﬁltration in the conjunctiva was achieved with
the treatment combination of anti-LFA-1 and anti ICAM-
1 monoclonal antibodies,28 compared with monotherapy
with either antibody. In murine endotoxin-induced uveitis,
a model for acute inﬂammation, Becker et al observed a
reduced number of inﬁltrating leukocytes in animals
receiving neutralizing antibodies for either LFA-1 or
ICAM-1.29
These preclinical studies constitute proof-of-concept ev-
idence for targeting integrin signaling in order to reduce
ocular surface inﬂammation. At the time these discoveries
were made, it became apparent to experts in the ﬁeld that
if a small molecule that blocked the interaction between
LFA-1 and ICAM-1 could be developed, it had the potential
to translate into clinical use.
III. DEVELOPMENT OF LIFITEGRAST, AN INTEGRIN
ANTAGONIST, AS A TREATMENT FOR DRY EYE
DISEASE
Liﬁtegrast is a novel small molecule integrin antagonist
that blocks the binding of ICAM-1 to LFA-1, thus interrupt-
ing the T cell-mediated inﬂammatory cycle.OL. 14 NO. 2 / www.theocularsurface.com
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Protein-protein interactions are central to a majority of
biological processes, and are challenging targets to tackle
with small molecule inhibitors.30 These interfaces are large,
complex, and difﬁcult to disrupt because of ﬂat surfaces or
less-deﬁned binding sites.
In 2002, Gadek et al described the identiﬁcation of a new
series of ICAM-1 mimics and LFA-1 antagonists.31 It was
hypothesized that ICAM-1 could act as a drug discovery
lead in the generation of small molecule therapeutics, and
the authors succeeded in transferring the binding epitope
of ICAM-1 to a small molecule framework. By examining
a whole host of molecules through combinatorial chemistry
and structure-activity relationship, Gadek et al demon-
strated that a molecule coded as Compound 4 (Figure 2)
directly inhibited the association of LFA-1 with ICAM-1
by binding to a high-afﬁnity site on LFA-1 (I domain of
the aL subunit).
Between 2010 and 2012, Zhong et al reported the discov-
ery and development of a potent tetrahydroisoquinoline
class of LFA-1/ICAM-1 antagonists,32-34 from which
liﬁtegrast35 (Compound 1g in Zhong et al32; Figure 2) was
identiﬁed as a promising drug candidate. The central tetra-
hydroisoquinoline moiety was designed to retain potency of
binding afﬁnity to LFA-1.
B. Mechanism of Action of Liﬁtegrast at the Molecu-
lar and Cellular Levels
Based on earlier work on putative ICAM-1 mimics and
LFA-1 antagonists (including Compound 4) by Gadek
et al31 and pre-discovery and development of liﬁtegrast, it
has been hypothesized that these molecules bind directly
to the ICAM-1 binding site on the I domain of the LFA-1
aL subunit and act as direct competitive antagonists to block
ICAM-1 binding.36 Alternative attempts to determine the
mechanism of inhibition of these compounds (including
Compound 4) via surface plasmon resonance experiments
suggested that these molecules might not be ligand mimetics
of ICAM-1, but that they instead bind to the I-like domain
of the LFA-1 b2 subunit in an allosteric fashion.
37 The
mechanism of action of liﬁtegrast (and other putative
ICAM-1 mimics and LFA-1 antagonists) was still under
debate until recently. At international congresses in 2013
and 2014, Semba et al reported additional ﬁndings on liﬁte-
grast itself, supporting the compound as a direct competitive
antagonist of the binding of ICAM-1 to LFA-1 (personal
communication, July 2015). In a live-cell experiment38
created to mimic the binding of LFA-1 to ICAM-1, it wasFigure 2. Molecular structures of Compound 431 and liﬁtegrast.32
THE OCULAR SURFACE / APRIL 2016, VOLfound that liﬁtegrast inhibited the formation and activation
of the IS by affecting LFA-1/ICAM-1 adhesion and by out-
competing ICAM-1 binding to LFA-1 in a dose-dependent
fashion. These results conﬁrmed earlier in vitro work
demonstrating the ability of liﬁtegrast to inhibit the attach-
ment of Jurkat T cells to ICAM-1.39
Liﬁtegrast inhibits the LFA-1/ICAM-1 interaction and as
a result should block the subsequent cycle of T cell-mediated
inﬂammation (Figure 3). Liﬁtegrast’s downstream effect on
cytokines has been reported in multiple preclinical studies.
The drug has been shown to reduce corneal inﬂammation
in mice by inhibiting neutrophil recruitment to the corneal
stroma,40 and to inhibit cytokine release from activated lym-
phocytes in vitro.39 Speciﬁcally, the inhibitory effect of liﬁte-
grast was signiﬁcant at 1 mM for IFN-g, IL-1b, IL-10, and
macrophage inﬂammatory protein 1a, cytokines and che-
mokines whose presence in tears correlates with the clinical
severity of DED.41 In the phase I clinical study,42 Semba et al
showed that tear concentrations of liﬁtegrast in healthy vol-
unteers reached, and in some instances exceeded, the target
ocular therapeutic level of >1 mM. Additionally, administra-
tion of liﬁtegrast was found to be efﬁcacious in 12 dogs of
various breeds, all prone to develop spontaneous keratocon-
junctivitis sicca.39 This body of preclinical evidence
conﬁrmed potent dose-dependent inhibition of liﬁtegrast
on the T cell activation, T cell recruitment, and cytokine
release steps in the inﬂammatory process (Figure 3), thus
suggesting that treatment with liﬁtegrast should decrease
the inﬂammatory response and reduce levels of proinﬂam-
matory mediators in patients with DED.
C. Liﬁtegrast: An Ophthalmic Agent for Treatment of
Dry Eye Disease
Topical administration is a minimally invasive therapy
for patients and has the advantage of increasing the selec-
tivity of a drug for its intended target. Nevertheless, deliv-
ering a drug to a speciﬁc site of action in the eye is still a
challenge for scientists. Liﬁtegrast was rationally designed
and developed to be topically administered as an ophthalmic
solution for treating DED. The compound was thus engi-
neered to have a favorable pharmacokinetic (PK) proﬁle
in the eye, with the following properties:
1) Strong inhibition of T cell adhesion to ICAM-1
expressing surfaces. Zhong et al demonstrated that liﬁ-
tegrast was potent in T cell adhesion assays, including
the HUT 78 T cell adhesion assay (half maximal
inhibitory concentration [IC50] ¼ 9 nM).32 Murphy
et al showed that liﬁtegrast strongly inhibited Jurkat
T cell attachment to ICAM-1 (IC50 ¼ 2.98 nM),39
thus conﬁrming that liﬁtegrast inhibits the recruit-
ment of T cells.
2) High solubility in aqueous media.32 Together with
drug permeability, solubility is one of the important
parameters that helps achieve desired drug concentra-
tions within targeted ocular tissues. Several tech-
niques exist to enhance solubility of a drug
compound in aqueous media, including chemical. 14 NO. 2 / www.theocularsurface.com 211
Figure 3. Mechanism of action (MOA) of liﬁtegrast at the cellular level. ICAM-1 ¼ intercellular adhesion molecule 1; LFA-1 ¼ lymphocyte function-
associated antigen 1; mAPC ¼ mature antigen-presenting cell; TH ¼ T helper cell. Disclaimer: this ﬁgure illustrates the current understanding of the
MOA of liﬁtegrast based on completed preclinical and clinical studies. Additional studies in the posterior ocular tissues and vascular system are
required to further elucidate the MOA of liﬁtegrast.
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LIFITEGRAST FOR TREATMENT OF DRY EYE / Perez, et almodiﬁcation by formation of a salt.43 Liﬁtegrast is
formulated as a sodium salt, which allows for concen-
trations of 100 mg/ml (10%) to be isotonic with
human tears at w300 mOsmol/l. Liﬁtegrast dosing
strengths of 50 mg/ml (5.0%) have been used in an-
imal and human studies to maintain the ophthalmic
solution at physiological pH.32 The liﬁtegrast formu-
lation currently under development for the treatment
of DED is a preservative-free 5.0% solution and as
such, the product is provided in single-unit dose vials.
Liﬁtegrast’s formulation is preservative free in order
to minimize aggravation of dry eye that can be caused
by such additives.44
3) Rapid absorption into ocular tissues. Animal models
have shown that greater rates of drug penetration
and delivery across barriers can be achieved as a
result of liﬁtegrast’s high intrinsic solubility and
good permeability. The ocular PK of liﬁtegrast was
determined by radiolabeled experiments in rats45
and dogs.39 Therapeutic levels of the drug were
observed in all ocular tissues, speciﬁcally in the bulbar
conjunctiva, palpebral conjunctiva, cornea, aqueous
humor, vitreous humor, and sclera, 30 min after a
single topical ocular administration of 14C-liﬁte-
grast.45 Ocular penetration also was investigated in
dogs, and this has conﬁrmed previous ﬁndings.39
Concentrations of radioactivity were determined to
be the highest in the anterior tissues (bulbar conjunc-
tiva, palpebral conjunctiva, and cornea) 30 min post
topical dosing. In the human diseased eye, the corneal
epithelium and stroma act as barriers between intra-
ocular tissues and the vascular system, thus limiting
the permeation of topically administered ophthalmic
drugs.46 In animals, drug levels in ocular tissues can
be determined directly through harvesting of the
eyes, unlike in humans. Serum plasma concentrations
of liﬁtegrast, determined from patient blood samples,
are an indirect measure of the drug’s ability to pene-
trate ocular tissues. Indeed, once a drug accesses pos-
terior ocular tissues, which are highly vascularized, it
is subjected to vascular absorption and clearance into
the systemic circulation. Peak plasma concentrations
of liﬁtegrast in subjects receiving a single drop of
the 5.0% formulation in the phase I clinical trial
were detected within 5 min of topical delivery in
the eye,42 thus conﬁrming the rapid absorption of liﬁ-
tegrast into human ocular tissues.
4) Rapid clearance from the systemic circulation. Rat
intravenous PK experiments showed a short half-life
(0.78 h), high clearance (139.2 ml/min/kg) and low
systemic exposure (area under the concentration
curve ¼ 705 h*ng/kg) for liﬁtegrast.32 This was
conﬁrmed in the phase I study in healthy subjects,
which established that low plasma levels of liﬁtegrast
were cleared within 1-4 hours of dosing.42 Addition-
ally, liﬁtegrast was shown to have good metabolicTHE OCULAR SURFACE / APRIL 2016, VOLstability in vitro in both human and rat liver micro-
somes (71% and >95%, respectively, after 30 min in-
cubation), which contain various drug-metabolizing
enzymes including cytochrome P450 (CYP450) en-
zymes.32 CYP450 enzymes are primarily found in
the liver, but they are known to be present in corneal
tissues and to participate in drug detoxiﬁcation.47,48
5) Good safety proﬁle in vitro and in vivo.32 The com-
pound was shown to be negative in the Ames test,
an assay used to determine whether a chemical can
cause mutations in the DNA of the test species (in
this instance, bacteria strains). Liﬁtegrast had low po-
tency in the CYP450 inhibition assay (CYP3A4 [one
of the major isoforms], IC50 >20 mM; CYP2C9,
IC50 ¼ 3.0 mM), which tests whether a chemical can
affect the activity of CYPs and thus potentially alter
drug metabolism in patients,49 thereby causing thera-
peutic inefﬁcacy or unanticipated adverse reactions.
Additionally, liﬁtegrast exhibited low potency in the
human ether-à-go-go-related gene assay (patch clamp,
IC50 >20 mM), which tests whether a chemical can
cause torsades de pointes, thus predisposing a patient
to sudden cardiac death. The phase I clinical study in
normal healthy adults42 conﬁrmed that liﬁtegrast was
well tolerated when administered in single and multi-
ple ascending doses. Speciﬁcally, subjects did not
experience any clinically meaningful changes in their
health assessments (vital signs, electrocardiogram,
and complete ophthalmologic exam).
In summary, liﬁtegrast is optimized for ocular use, with
an excellent PK proﬁle and a very low systemic exposure.
Hence, it is expected to work effectively in the human eye
without systemic side effects.
Liﬁtegrast is currently in late phase III development. The
liﬁtegrast clinical development program is the largest of its
kind; it began in 2008 and has enrolled >1,800 patients
with DED (placebo and liﬁtegrast groups). Four clinical
studies (3 efﬁcacy and safety studies and 1 long-term expo-
sure safety study) have been completed to date, with further
research in progress. Evidence of the efﬁcacy and safety of
liﬁtegrast in patients with DED has been observed in the
following clinical studies, which were carried out exclusively
in the United States.
In a phase II clinical study (ClinicalTrials.gov identiﬁer,
NCT00926185),50 the group of subjects treated with liﬁte-
grast ophthalmic solution 5.0% did not show a statistically
signiﬁcant difference from the placebo group for the single
primary efﬁcacy endpoint (sign), mean inferior corneal
staining score (ICSS) at day 84 (last visit, week 12). A pre-
speciﬁed secondary sign endpoint, mean (standard devia-
tion, SD) change in ICSS from baseline to day 84 (from
week 0 to week 12), showed a signiﬁcant response for the
liﬁtegrast ophthalmic solution 5.0% group compared with
placebo (0.05 [0.773] vs 0.40 [0.802], P¼.021). Signiﬁcant
improvements in a prespeciﬁed secondary symptom
endpoint (change on the visual-related function subscale. 14 NO. 2 / www.theocularsurface.com 213
LIFITEGRAST FOR TREATMENT OF DRY EYE / Perez, et alof a symptom scale) also were noted from baseline to day 84
in the liﬁtegrast group compared with placebo (0.30
[0.934] vs 0.07 [0.929], P¼.039).50
Following the promising ﬁndings in the phase II study,
the OPUS-1 phase III clinical study (ClinicalTrials.gov iden-
tiﬁer, NCT01421498)51 was conducted between 2011 and
2012, with coprimary objective (sign) and subjective (symp-
tom) efﬁcacy endpoints. Analysis of study results showed
that the mean (SD) change from baseline to day 84 in
ICSS was greater in the liﬁtegrast ophthalmic solution
5.0% group compared with placebo (0.07 [0.868] vs 0.17
[0.819], P<.001). The symptom coprimary endpoint
(change on the visual-related function subscale) was not
met in this study. However, improvements were noted at
day 84 in ocular discomfort in the liﬁtegrast group
compared with placebo (1.10 [1.153] vs 1.31 [1.182],
P¼.027) and eye dryness in the liﬁtegrast group compared
with placebo (25.00 [28.870] vs 30.39 [30.773], P¼.029).51
The OPUS-2 phase III clinical study (ClinicalTrials.gov
identiﬁer, NCT01743729)52 was conducted between 2012
and 2013, with coprimary sign and symptom efﬁcacy end-
points. Study results showed that subjects treated with liﬁte-
grast ophthalmic solution 5.0% experienced greater
improvement in eye dryness score (mean [SD] change
from baseline to day 84) than subjects treated with placebo
(35.30 [28.400] vs 22.75 [28.600], P<.001). Additionally,
nominally signiﬁcant improvements were noted in the sec-
ondary symptom endpoints ocular discomfort in the liﬁte-
grast group compared with placebo (0.91 [1.280]
vs 0.57 [1.354], nominal P<.001), and eye discomfort in
the liﬁtegrast group compared with placebo (26.46
[31.328] vs 16.73 [31.207], nominal P<.001). The sign
coprimary endpoint (mean change from baseline to day 84
in ICSS) was not met in this study.52 In the phase II,
OPUS-1 and OPUS-2 studies, liﬁtegrast was generally well
tolerated and there were no serious ocular treatment-
emergent adverse events.
The SONATA long-term safety study (ClinicalTrials.gov
identiﬁer, NCT01636206) of liﬁtegrast ophthalmic solution
5.0% is completed. Results from this study were presented
at congresses in 2015 and provided further evidence of the
safety of liﬁtegrast. Full results will be published separately.
The OPUS-3 phase III clinical study (ClinicalTrials.gov
identiﬁer, NCT02284516) is completed. Results will be pub-
lished separately.IV. CONCLUSION
Integrin inhibitors have been found to have potent anti-
inﬂammatory effects in several autoimmune/inﬂammatory
diseases. Targeting speciﬁc inﬂammation steps, including
integrins and cytokines, is a promising avenue for the devel-
opment of new and effective therapeutic interventions in
DED. Liﬁtegrast is a novel integrin antagonist speciﬁcally
developed to target the LFA-1 (an integrin) and ICAM-1
(an intercellular adhesion molecule) interaction. Liﬁtegrast
inhibits T cell recruitment, T cell activation, and subsequent214 THE OCULAR SURFACE / APRIL 2016, Vcytokine release, thereby targeting a speciﬁc inﬂammatory
pathway involved in the pathogenesis of DED.
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